I want to introduce my client partner, http://www.4catalyzer.com, founded by Jonathan Rothberg, and their newest genomics start-up company, 454. We are actively looking for a senior-level Molecular Biologist to join us for a GROUND FLOOR opportunity.
454 is a group of leading genomics experts who are developing a DNA sequencing platform for use at home, for under $100 – it’s an innovative product and an exciting time to join the team!
You would play a critical role & work with the company’s founders to develop next-gen molecular biology systems to interface with novel engineering platforms. We're looking for someone with experience in:
- library preparation and amplification on a solid support
- DNA patterned array design, development, and production
Here is the role: https://www.linkedin.com/jobs/view/3362957271
Please get in touch for more information - happy to provide full details.
The lab is currently in Guilford, CT, and will be opening in Miami, FL, in 2023.

https://www.aplitrak.com/?adid=Uy5aaXRvLjAzNDc5LjU0MDNAbm9uc3RvcHBoYXJtYS5hcGxpdHJhay5jb20

Scientists have discovered a new treatment that slows the progression of neurodegenerative disease in mice. The breakthrough research may offer hope in tackling currently untreatable conditions such as Alzheimer’s disease (AD).
The study, led by researchers at the University of Glasgow’s new Advanced Research Centre (ARC). discovered that by using a novel drug – which selectively activates a brain protein called the M1-receptor – the lifespan of mice suffering from neurodegeneration could be extended.
At present, treatments for AD can only target symptoms, including memory impairment, and previous attempts to establish a drug that can slow down the disease have been unsuccessful.
The study demonstrates how many of the features of human AD, including memory loss and brain inflammation, could be treated in mice when they were given the new drug, known as a positive allosteric modulator or M1-PAM. The study also indicated that, in addition to treating symptoms, M1-PAMs may also be able to slow the overall progression of the disease.
https://www.pharmatimes.com/news/research_provides_hope_for_patients_with_neurodegenerative_disease_1480816

The U.S. health regulator on Tuesday issued an emergency use authorization to Roche's test for the detection of DNA from monkeypox virus in swab specimens collected from people suspected of the virus infection.
The tests will be conducted on the Swiss company's cobas systems, which can also detect HIV, hepatitis B and C viruses.
The Food and Drug Administration said testing will be limited to laboratories that meet the requirements to perform moderate or high complexity tests.
While around 80,000 cases of monkeypox have been reported in nearly 100 countries since the outbreak started earlier this year, the number of cases have declined from the peak in August. Over 28,000 cases have been reported in the United States in the outbreak this year, including two deaths.
Read more:
https://www.reuters.com/business/healthcare-pharmaceuticals/us-fda-authorizes-roches-monkeypox-test-2022-11-15/

Janssen – a pharmaceutical arm of Johnson & Johnson – has announced that Tecvayli (teclistamab-cqyv) has been approved by the US Food and Drug Administration (FDA) for the treatment of adult patients with relapsed or refractory multiple myeloma (RRMM).
Specifically, patients treated with Tecvayli must have received four or more prior lines of therapy, including a proteasome inhibitor, immunomodulatory drug and anti-CD38 monoclonal antibody.
The FDA’s decision is supported by evidence from the pivotal phase 2 MajesTEC-1 clinical trial in RRMM patients who had received a median of five prior lines of therapy.
An overall response rate of 61.8% was achieved in the study, notably with 28.2% of patients achieving a complete response or better, the company reported.
The median time to first response was 1.2 months and, with a median follow-up of 7.4 months, the estimated duration of response rate was 90.6% at six months and 66.5% at nine months.
Read more: https://www.pmlive.com/pharma_news/janssens_tecvayli_granted_fda_approval_for_multiple_myeloma_1479795

How can life science companies apply safety signaling and real-world records to achieve better healthcare outcomes?
Register here: https://globalmeet.webcasts.com/starthere.jsp?ei=1569315&tp_key=da05f61731&sti=oracle 
With Oracle’s recent acquisition of Cerner, new opportunities are emerging for this collaboration to improve the safety of medical products.
Oracle’s market-leading safety software solutions provide highly powerful technology and algorithms for data mining. Combining Cerner Enviza’s real-world datasets containing de-identified, person-centric, longitudinal records offers a vast resource for expanding the potential of safety signaling.

Merck & Co – known as MSD outside the US and Canada – has exercised its option to jointly develop and commercialise personalised cancer vaccine (PCV), mRNA-4157/V940, with Moderna in accordance with the terms of its existing collaboration and licence agreement.
Under the agreement, originally established in 2016 and amended in 2018, Moderna will receive an upfront payment of $250m from Merck, with the two companies sharing the costs and any profits equally under this worldwide collaboration.
PCVs are designed to prime the immune system so that a patient can generate a tailored antitumour response to their tumour mutation signature to treat their cancer.
mRNA-4157/V940 is currently being evaluated in combination with Keytruda, Merck’s anti-PD-1 therapy, in a phase 2 clinical trial being conducted by Moderna for the adjuvant treatment of patients with high-risk melanoma. Keytruda was selected as the comparator in the trial because it is considered a standard-of-care for high-risk melanoma patients, the companies outlined.
In the trial, following complete surgical resection, patients were randomised to receive mRNA-4157/V940 (nine doses every three weeks) and Keytruda (200mg every three weeks) versus Keytruda alone for approximately one year until disease recurrence or unacceptable toxicity.
The primary endpoint of the trial is recurrence-free survival, with secondary endpoints including distant metastasis-free survival and overall survival. The trial is fully enrolled and primary data is expected in the fourth quarter of 2022.
Read more: https://www.pmlive.com/pharma_news/merck_and_moderna_to_jointly_develop_personalised_cancer_vaccine_in_$250m_deal_1456720

In this episode of Healthcare Goes Digital, Lawrence Bressler, Head of Value & Market Access, Global Rare Diseases at Chiesi, sat down with Natalie Yeadon, Co-founder & CEO of Impetus Digital. Among other things, he shared how Chiesi is revolutionizing the lives of people living with rare diseases on a global scale. He also discussed key ways for life science companies to engage with patient communities, the importance of pharmaceutical companies maintaining high social and environmental standards, current market access barriers, and more.

GSK’s Boostrix (tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine adsorbed [Tdap]) has been approved by the US Food and Drug Administration (FDA) for immunisation during the third trimester of pregnancy to help prevent pertussis (whooping cough) in infants less than two months of age, the company announced.
Pertussis is a highly contagious respiratory infection caused by the bacterium Bordetella pertussis. Severity of the disease varies, but infants are at a high risk of complications because their immune systems are still developing.
According to the Centers for Disease Control and Prevention, 4.2% of the total cases of pertussis reported in the US in 2021 were in infants younger than six months of age and approximately 31% required hospitalisation.
“While vaccination is the best method for providing protection, infants younger than two months of age are too young to be protected by the childhood pertussis vaccine series. This is the first vaccine approved specifically for use during pregnancy to prevent a disease in young infants whose mothers are vaccinated during pregnancy,” explained Peter Marks, director of the FDA’s Center for Biologics Evaluation and Research.
Read more: https://www.pmlive.com/pharma_news/gsks_boostrix_approved_by_fda_for_use_during_pregnancy_to_prevent_whooping_cough_in_infants_1456660

Dr. Luca Dezzani, VP of US Oncology Medical Affairs at Johnson & Johnson, explores innovation in Medical Affairs, new technologies for data dissemination and medical education, how to engage with different healthcare stakeholders, plus much more.

https://www.linkedin.com/feed/update/urn:li:activity:6980523970336849920

Kaitlin Anstett, Senior Medical Advisor at Theratechnologies, shares her unique insights into the way Medical Affairs teams are changing the way they are engaging and interacting with their most important stakeholders in the “new normal.” She is also diving into topics related to patient-centricity and digital technologies in Pharma, including how these can be used to support HCPs and patients during this challenging time.

I'm anxious to create content for this exciting new field of investigation.

Search Now - https://phrmwb.com/3JqeYL5
- Clinical Research (1,937) - https://phrmwb.com/3d2FLRi
- R & D (608) - https://phrmwb.com/3JqplOV
- Sales / Commercial (464) - https://phrmwb.com/3P7Cwpr
- Data Management / Statistics (396) - https://phrmwb.com/3bmzuQ6
- Project Management (310) - https://phrmwb.com/3OSiOO4
- Quality (247) - https://phrmwb.com/3oPqXbG
- Regulatory Affairs (213) - https://phrmwb.com/3JoLbSY
- Medical Communications (210) - https://phrmwb.com/3OUG9yy
- Finance / Administration (168) - https://phrmwb.com/3OTkjvp
- Medical Affairs (164) - https://phrmwb.com/3oOwMpz
- Manufacturing (161) - https://phrmwb.com/3JqeQLB
- Marketing (134) - https://phrmwb.com/3JvM3Fp
- HEOR (132) - https://phrmwb.com/3Jmj07g
- Operations (121) - https://phrmwb.com/3JpW2fB
- Information Technology (120) - https://phrmwb.com/3bmEQuC
- Healthcare (95) - https://phrmwb.com/3oK1i49
- HR / Recruitment / Training (73) - https://phrmwb.com/3JqKZm1
Register & Upload Your CV Now! https://phrmwb.com/3oLPbmS
Follow us on LinkedIn: https://www.linkedin.com/company/pharmiweb-jobs/

Fresher with MSc microbiology, 2022 degree (9.47 cpi)